Identifying diabetogenic drugs using real world health care databases: A Danish and Australian symmetry analysis
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.14982 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Lars Christian Lund und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
Drug‐induced diabetes is underreported in conventional drug safety monitoring and may contribute to the increasing incidence of type 2 diabetes. Therefore, we used routinely collected prescription data to screen all commonly used drugs for diabetogenic effects.
Methods
Leveraging the Danish nationwide health registries, we used a case‐only symmetry analysis design to evaluate all possible associations between drug initiation and subsequent diabetes. The study was conducted among individuals aged ≥40 years with a first‐ever prescription for any antidiabetic drug 1996‐2018 (n = 348 996). Sequence ratios (SRs) and 95% confidence intervals (CIs) were obtained for all possible drug class‐diabetes combinations. A lower bound of the 95% CI >1.00 was considered a signal. Signals generated in Denmark were replicated using the Services Australia, Pharmaceutical Benefits Scheme 10% data extract.
Results
Overall, 386 drug classes were investigated, of which 70 generated a signal. In total, 43 were classified as previously known based on the SIDER database or a literature review, for example, glucocorticoids (SR 1.67, 95% CI 1.62‐1.72) and β‐blockers (SR 1.20, 95% CI 1.16‐1.23). Of 27 new signals, three drug classes yielded a signal in both the Danish and Australian data source: digitalis glycosides (SR 2.15, 95% CI 2.04‐2.27, and SR 1.76, 95% CI 1.50‐2.08), macrolides (SR 1.20, 95% CI 1.16‐1.24, and SR 1.11, 95% CI 1.06‐1.16) and inhaled β2‐agonists combined with glucocorticoids (SR 1.35, 95% CI 1.28‐1.42, and SR 1.14, 95% CI 1.06‐1.22).
Conclusion
We identified 70 drug‐diabetes associations, of which 27 were classified as hitherto unknown. Further studies evaluating the hypotheses generated by this work are needed, particularly for the signal for digitalis glycosides.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.
- Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.
- Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
- Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
ORCID-Profile: Lars Christian Lund, Anton Pottegård, Morten Andersen, Nicole Pratt, Jesper Hallas
Zitieren
APA
Lund, L. C., Jensen, P. H., Pottegård, A., Andersen, M., Pratt, N., & Hallas, J. (2023). Identifying diabetogenic drugs using real world health care databases: A Danish and Australian symmetry analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14982
Vancouver
Lund LC, Jensen PH, Pottegård A, Andersen M, Pratt N, Hallas J. Identifying diabetogenic drugs using real world health care databases: A Danish and Australian symmetry analysis. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.14982
BibTeX
@article{Lund2023,
author = {Lund, Lars Christian and Jensen, Patricia Hjorslev and Pottegård, Anton and Andersen, Morten and Pratt, Nicole and Hallas, Jesper},
title = {Identifying diabetogenic drugs using real world health care databases: A Danish and Australian symmetry analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.14982}
}
EUVIMED